In addition, an update of the drivers of the Swedish drug budget, including to what extent orphan drugs impact the overall budget, will be given by Per Troein, VP Supplier & Assoc Relations, responsible for the underlying analysis completed for Socialstyrelsen’s autumn update to the Government.
8.00 – 8.30 Breakfast is served
8.30 – 9.10 Rare disease market in the US – Murray Aitken
9.10 – 9.30 Orphan drugs budget impact in Sweden – Per Troein
9.30 – 10.00 Open time for questions